Human Beta-1,4-galactosyltransferase 1(B4GALT1) ELISA kit

Code CSB-EL002513HU
Size 96T,5×96T,10×96T
Price Request a Quote or Start an on-line Chat
Trial Size 24T ELISA Kit Trial Size (Only USD$150/ kit)
* Sample kit cost can be deducted as a $30 credit for each 96-assay kit of the same analyte and brand you subsequently purchase in six months till depleted. Apply now

Product Details

Target Name
UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1
Alternative Names
B4GALT1; GGTB2; Beta-1,4-galactosyltransferase 1; Beta-1,4-GalTase 1; Beta4Gal-T1; b4Gal-T1; Beta-N-acetylglucosaminyl-glycolipid beta-1,4-galactosyltransferase; Beta-N-acetylglucosaminylglycopeptide beta-1,4-galactosyltransferase; Lactose synthase A protein; N-acetyllactosamine synthase; Nal synthase; Neolactotriaosylceramide beta-1,4-galactosyltransferase; UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1; UDP-galactose:beta-N-acetylglucosamine beta-1,4-galactosyltransferase 1
Uniprot No.
Homo sapiens (Human)
Sample Types
serum, plasma, cell lysates, tissue homogenates
Detection Range
0.156 ng/mL-10 ng/mL
0.039 ng/mL
Assay Time
Sample Volume
Detection Wavelength
450 nm
Research Area
Signal Transduction
Assay Principle
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human B4GALT1 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
  Sample Serum(n=4)
1:1 Average % 96
Range % 90-102
1:2 Average % 89
Range % 84-95
1:4 Average % 91
Range % 87-99
1:8 Average % 92
Range % 88-96
The recovery of human B4GALT1 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample Type Average % Recovery Range
Serum (n=5) 86 80-90
EDTA plasma (n=4) 100 95-108
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1 OD2 Average Corrected
10 2.201 2.153 2.177 2.022
5 1.731 1.659 1.695 1.540
2.5 1.291 1.264 1.278 1.123
1.25 0.836 0.892 0.864 0.709
0.625 0.647 0.670 0.659 0.504
0.312 0.393 0.375 0.384 0.229
0.156 0.264 0.271 0.268 0.113
0 0.153 0.156 0.155  
and FAQs
Store at 2-8°C. Please refer to protocol.
Lead Time
3-5 working days after you place the order, and it takes another 3-5 days for delivery via DHL or FedEx

This Human B4GALT1 ELISA Kit was designed for the quantitative measurement of Human B4GALT1 protein in serum, plasma, cell lysates, tissue homogenates. It is a Sandwich ELISA kit, its detection range is 0.156 ng/mL-10 ng/mL and the sensitivity is 0.039 ng/mL.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

(From Uniprot)
The Golgi complex form catalyzes the production of lactose in the lactating mammary gland and could also be responsible for the synthesis of complex-type N-linked oligosaccharides in many glycoproteins as well as the carbohydrate moieties of glycolipids.; The cell surface form functions as a recognition molecule during a variety of cell to cell and cell to matrix interactions, as those occurring during development and egg fertilization, by binding to specific oligosaccharide ligands on opposing cells or in the extracellular matrix.
Gene References into Functions
  1. Human beta-1,4-GalT1 is a constitutively expressed mesangial cell IgA receptor with an important role in both mesangial IgA clearance and the initial response to IgA deposition. PMID: 28750925
  2. Increased B4GALT1 expression is a potential independent adverse prognostic factor for overall survival in patients with non-metastatic clear cell renal cell carcinoma. PMID: 27092876
  3. demonstrated that ZFX is aberrantly expressed in multiple human leukemic cells and it modulates the growth and drug response of leukemic cells partially via B4GALT1, which suggests that ZFX is a new regulator of leukemic cells and warrants intensive investigations on this 'stemness' regulator in these deadly diseases PMID: 27797721
  4. High B4GALT1 expression is associated with aging. PMID: 26840264
  5. We suggest that the unique expression patterns for the B4GALT1 in normal and malignant tissues are controlled by a differential usage of 5'-B4GALT1 regulatory units along with a post-transcriptional regulation by the antisense RNA PMID: 26315939
  6. Human chorionic gonadotropin provides a mechanism to bridge embryo to endometrium through beta1,4-GalT. PMID: 26191157
  7. HS5 cells had significantly enhanced levels of bisecting N-glycans (catalyzed by MGAT3 whereas HS27a cells had enhanced levels of Galbeta1,4GlcNAc. PMID: 25936519
  8. plays a role in activation of T-lymphocytes and participates in intercellular contact formation PMID: 25223470
  9. B4GALT1 and B4GALT5, two members of B4GALT gene family, are involved in the development of multidrug resistance of human leukemia cells. PMID: 23744354
  10. the glycogene B4GALT1 represent a valuable candidate biomarker of invasive phenotype of colorectal cancer. PMID: 22927297
  11. RNAi-mediated knockdown of beta1,4GT1 increased the levels of EGFR dimerization and phosphorylation. These data suggest that cell surface beta1,4GT1 interacts with EGFR and inhibits EGFR activatio PMID: 23583406
  12. estrogen regulates the expression of B4GALT1 through the direct binding of ER-alpha to ERE; the expressed B4GALT1 plays a crucial role in the proliferation of MCF-7 cells through its activity as a membrane receptor. PMID: 22982306
  13. Osteopontin increases the expression of beta1, 4-Galactosyltransferase-I and promotes adhesion in human RL95-2 cells, the activity critical for embryo implantation. PMID: 22847114
  14. expression of beta1,4-GalT-I increased in the cartilage and synovial tissue of osteoarthritis (OA) patients compared with healthy controls; data suggest that beta1,4-GalT-I may play an important role in the inflammatory processes in cartilage and synovial tissue of patients with OA PMID: 21750942
  15. beta4Gal-T1 molecule has two different oligosaccharide binding regions for the binding of the extended oligosaccharide moiety of the acceptor substrate. PMID: 22740701
  16. TNF-alpha contributes to the up-regulation of beta1,4-GalT-I mRNA in human fibroblast-like synoviocytes. PMID: 20886274
  17. These results suggested that beta1,4-Galactosyltransferase-I may play an important role in the inflammatory processes in synovial tissue of patients with rheumatoid arthritis. PMID: 20490888
  18. B4GalTI might act as a key adhesion molecule participating in T cell-dendritic cell contacts. PMID: 20851383
  19. PKC signal transduction pathway participates in regulating beta-1, 4-GalT-I expression in endothelial cells stimulated by TNF-alpha. PMID: 20619088
  20. The mutation of C80S introduces a fully occupied UDP binding site at the enzyme dimer interface that is observed to be dependent on the binding of H antigen acceptor analog. PMID: 20655926
  21. Golgi N-glycosyltransferases beta-1,2-N-acetylglucosaminyltransferase I, beta-1,2-N-acetylglucosaminyltransferase II, 1,4-galactosyltransferase I, and alpha-2,6-sialyltransferase I form both homo- and heterodimeric enzyme complexes in live cells PMID: 20378551
  22. found that both the long and short isoforms of beta-1,4-GalT-I were expressed in human CD4(+) T lymphocytes, and localized in the cytoplasm and on the plasma membrane. PMID: 20202494
  23. deficiency causes a new congenital disorder of glycosylation (CDG), designated type IId (CDG-IId), a severe neurologic disease characterized by hydrocephalus, myopathy, and blood-clotting defects PMID: 11901181
  24. TNFalpha modulates the glycosylation of endothelial cells by a mechanism that directly enhances the stability of beta4GalT-1 mRNA transcripts PMID: 15668241
  25. beta4Gal-T1 interacts preferentially with the 1,2-1,6-arm trisaccharide rather than with the 1,2-1,3-arm or 1,4-1,3-arm of a bi- or tri-antennary oligosaccharide chain of N-glycan PMID: 16157350
  26. Data show that expression of a hybrid enzyme of Arabidopsis thaliana xylosyltransferase and human beta-1,4-galactosyltransferase I in tobacco causes a reduction of N-glycans with potentially immunogenic core-bound xylose and fucose residues. PMID: 16675551
  27. These results demonstrated that cell surface beta1,4GT1 may negatively regulate cell survival possibly through inhibiting and modulating EGFR signaling pathway. PMID: 16786197
  28. Cycling between the trans-Golgi cisterna and the trans-Golgi network of galT is signal mediated. PMID: 17021253
  29. hepatitis B-induced GalT I expression might contribute to hepatitis B-mediated hepatocellular carcinoma development and progression PMID: 18929424
  30. Deoxygenated disaccharide analogs as specific inhibitors of beta1-4-galactosyltransferase 1 and selectin-mediated tumor metastasis. PMID: 19106107
  31. These results demonstrate that B3GNT1 and B4GALT1 physically associate in vitro and in cultured cells, providing insight into possible mechanisms for regulation of polyLacNAc production. PMID: 19261593

Show More

Hide All

Involvement in disease
Congenital disorder of glycosylation 2D (CDG2D)
Subcellular Location
[Isoform Long]: Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein. Cell membrane; Single-pass type II membrane protein. Cell surface. Cell projection, filopodium.; [Isoform Short]: Golgi apparatus, Golgi stack membrane; Single-pass type II membrane protein.; [Processed beta-1,4-galactosyltransferase 1]: Secreted.
Protein Families
Glycosyltransferase 7 family
Tissue Specificity
Ubiquitously expressed, but at very low levels in fetal and adult brain.
Database Links

HGNC: 924

OMIM: 137060

KEGG: hsa:2683

STRING: 9606.ENSP00000369055

UniGene: Hs.272011

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1